(Q50558649)

15 March 2018

title

Estimating the likelihood of sustained virological response in chronic hepatitis C therapy. (English)

1 reference

15 March 2018

0 references

1 reference

S Mauss

1

1 reference

15 March 2018

D Hueppe

2

1 reference

15 March 2018

C John

3

1 reference

15 March 2018

J Goelz

4

1 reference

15 March 2018

R Heyne

5

1 reference

15 March 2018

B Moeller

6

1 reference

15 March 2018

R Link

7

1 reference

15 March 2018

G Teuber

8

1 reference

15 March 2018

A Herrmann

9

1 reference

15 March 2018

M Spelter

10

1 reference

15 March 2018

S Wollschlaeger

11

1 reference

15 March 2018

A Baumgarten

12

1 reference

15 March 2018

K-G Simon

13

1 reference

15 March 2018

N Dikopoulos

14

1 reference

15 March 2018

T Witthoeft

15

1 reference

15 March 2018

publication date

16 September 2010

1 reference

15 March 2018

Journal of Viral Hepatitis

published in

1 reference

15 March 2018

volume

18

1 reference

15 March 2018

issue

4

1 reference

15 March 2018

page(s)

e81-90

1 reference

15 March 2018

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01372.X

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01372.X

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01372.X

Diagnosis, management, and treatment of hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01372.X

Management and treatment of hepatitis C viral infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center program and the National Hepatitis C Program office

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01372.X

New hepatitis C guidelines for the Asia-Pacific region: APASL consensus statements on the diagnosis, management and treatment of hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01372.X

Impact of adherence on the outcome of antiviral therapy for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01372.X

Peginterferon alfa-2a in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01372.X

Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01372.X

Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01372.X

Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01372.X

Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) plus ribavirin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01372.X

Response rates to combination therapy for chronic HCV infection in a clinical setting and derivation of probability tables for individual patient management

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01372.X

A study of best positive predictors for sustained virologic response to interferon alpha plus ribavirin therapy in naive chronic hepatitis C patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01372.X

Predictors of response of US veterans to treatment for the hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01372.X

Safety, tolerability and efficacy of peginterferon alpha-2a and ribavirin in chronic hepatitis C in clinical practice: The German Open Safety Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01372.X

Treatment of chronic he1patitis C genotype 1 with peginterferon-alpha2a (40 kDa) plus ribavirin under routine clinical practice in Spain: early prediction of sustained virological response rate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01372.X

Hepatic steatosis in chronic hepatitis C virus infection: prevalence and clinical correlation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01372.X

Role of gamma-glutamyl transferase activity in patients with chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01372.X

Factors affecting treatment responses to interferon-alpha in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01372.X

Gamma-glutamyl transferase (GGT) as an independent predictive factor of sustained virologic response in patients with hepatitis C treated with interferon-alpha and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01372.X

Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01372.X

Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01372.X

Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at high-risk for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01372.X

Liver fibrosis is associated with decreased peripheral platelet count in patients with chronic hepatitis B and C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01372.X

The role of thrombopoietin in the thrombocytopenia of patients with liver cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01372.X

Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01372.X

Associations between hepatitis C viremia and low serum triglyceride and cholesterol levels: a community-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01372.X

Scientific rationale and study design of the individualized dosing efficacy vs flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01372.X

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01372.X

10.1111/J.1365-2893.2010.01372.X

21 January 2018

Identifiers

DOI

1 reference

15 March 2018

PubMed ID

20849436

1 reference

15 March 2018